These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33399228)

  • 1. Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response.
    Sweeney KJ; Tetzlaff MT; Vega F; Gillenwater A; Zuo Z; Gross N; Nagarajan P; Wargo J; Nelson K; Prieto VG; Torres-Cabala CA; Curry JL
    J Cutan Pathol; 2021 May; 48(5):674-679. PubMed ID: 33399228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.
    Zhao X; Yue D; Qian J; Zhang L; Song J; Zhang B; Zhang C; Sun L; Ma Y; Zhang H; Wang C
    Front Immunol; 2022; 13():794217. PubMed ID: 35173719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
    Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
    BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
    Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
    Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
    Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Kaufman HL; Seebach F; Lowy I; Yoo SY; Mathias M; Fenech K; Han H; Fury MG; Rischin D
    N Engl J Med; 2022 Oct; 387(17):1557-1568. PubMed ID: 36094839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
    Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
    Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological potential of tertiary lymphoid structures surrounding the primary tumor in gastric cancer.
    Yamakoshi Y; Tanaka H; Sakimura C; Deguchi S; Mori T; Tamura T; Toyokawa T; Muguruma K; Hirakawa K; Ohira M
    Int J Oncol; 2020 Jul; 57(1):171-182. PubMed ID: 32319601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.
    Mallardo D; Sparano F; Vitale MG; Trojaniello C; Fordellone M; Cioli E; Esposito A; Festino L; Mallardo M; Vanella V; Facchini BA; De Filippi R; Meinardi P; Ottaviano M; Caracò C; Simeone E; Ascierto PA
    Cancer Immunol Immunother; 2024 Jun; 73(8):160. PubMed ID: 38850335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
    Kacew AJ; Harris EJ; Lorch JH; Haddad RI; Chau NG; Rabinowits G; LeBoeuf NR; Schmults CD; Thakuria M; MacConaill LE; Hanna GJ
    Eur J Cancer; 2019 May; 113():1-9. PubMed ID: 30954880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case Report of Small Lymphocytic Lymphoma Mimicking Primary Cutaneous Marginal Zone Lymphoma With Plasmacytic Differentiation.
    Smith SDB; Aggarwal A; Chen W; Nava VE
    Am J Dermatopathol; 2021 Oct; 43(10):730-731. PubMed ID: 33606375
    [No Abstract]   [Full Text] [Related]  

  • 11. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
    Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cemiplimab in advanced cutaneous squamous cell carcinoma.
    Naik PP
    Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tertiary lymphoid structures in tongue cancer: Association with clinicopathological parameters, preoperative S-1 chemotherapy response, and prognosis.
    Seki M; Sano T; Saito E; Ogawa M; Yokoo S; Oyama T
    J Oral Pathol Med; 2024 Feb; 53(2):124-132. PubMed ID: 38183312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
    Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
    Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
    Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
    Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C
    J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
    Lee A; Duggan S; Deeks ED
    Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
    Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
    Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma.
    Geidel G; Adam L; Rünger A; Menz A; Kött J; Haalck T; Gebhardt C
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1414-e1416. PubMed ID: 37458533
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.